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Background: Only three observational studies investigated whether exposure to antipsychotics is associated with
an increased risk of pulmonary embolism, with conflicting results. This study was therefore carried out to establish
the risk of pulmonary embolism associated with antipsychotic drugs, and to ascertain the risk associated with first- and
second-generation antipsychotic drugs, and with exposure to individual drugs.
Methods: We identified 84,253 adult individuals who began antipsychotic treatment in a large Italian health care
system. Cases were all cohort members who were hospitalized for non-fatal or fatal pulmonary embolism during
follow-up. Up to 20 controls for each case were extracted from the study cohort using incidence density sampling
and matched by age at cohort entry and gender. Each individual was classified as current, recent or past antipsychotic
user. The occurrence non-fatal or fatal pulmonary embolism was the outcome of interest.
Results: Compared to past use, current antipsychotic use more than double the risk of pulmonary embolism (odds
ratio 2.31, 95% confidence interval 1.16 to 4.59), while recent use did not increase the risk. Both conventional and
atypical antipsychotic exposure was associated with an increase in risk, and the concomitant use of both classes
increased the risk of four times (odds ratio 4.21, 95% confidence interval 1.53 to 11.59).
Conclusions: Adding the results of this case–control study to a recent meta-analysis of three observational studies
substantially changed the overall estimate, which now indicates that antipsychotic exposure significantly increases the
risk of pulmonary embolism.Background
Pulmonary embolism (PE) is a significant cause of mor-
bidity and mortality, occurring at an estimated 95 cases
per 100,000 patient-years [1,2]. The severity of PE ranges
from asymptomatic, incidentally discovered subsegmental
thrombi to hemodynamically unstable, life-threatening
episodes, and sudden death [3,4].
In 1997 Walker and colleagues conducted an epidemio-
logical study suggesting that exposure to clozapine, an
agent belonging to the group of the so-called second-
generation antipsychotic (AP) drugs, significantly increased
the risk of PE mortality [5]. Since then, other epidemio-
logical cohort and case control studies provided additional* Correspondence: corrado.barbui@univr.it
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unless otherwise stated.data on this association [6]. A recent systematic review and
meta-analysis identified 13 studies, of which only three in-
vestigated PE outcomes, while ten estimated the association
between AP exposure and risk of a composite outcome
which included deep venous thrombosis, femoral vein
thrombi, popliteal vein thrombi, iliac vein thrombi, deep
vessels of lower extremity thrombophlebitis, and pulmonary
embolism [7]. Analysis of the three PE studies failed to de-
tect a significant association between exposure to APs and
risk of PE outcomes (odds ratio 4.90, 95% confidence inter-
val 0.77 to 30.98), but the confidence interval was very wide
and included the possibility of substantial harm [7].
Therefore, we investigated whether exposure to AP
drugs is associated with an increased risk of PE, and
ascertained the risk associated with first- and second-
generation AP drugs, and with exposure to individual
drugs. We carried out a nested case–control study using
a large administrative database in the health system ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ary aim, we updated the published meta-analysis with
the results of this study, using the same methodology.
Methods
Setting and data source
Lombardy is the largest and the most affluent region in
Italy, with a population of around 10 million inhabitants.
Lombardy is located in the northernmost part of the
country and includes the metropolitan area of Milan,
Italy’s second largest city.
The data used for this study were retrieved from the
Regional Health Service (RHS) databases of Lombardy
[8,9]. These databases include: i) demographic and admin-
istrative information on all residents in the Lombardy
region; ii) all community (outside the hospital) drug
prescriptions reimbursed by the RHS; iii) all public and
private hospital discharge forms, with diagnoses ac-
cording to the ICD-9-CM. According to local regula-
tions on administrative database analyses, no formal
approval of the study protocol was required; however,
as previously reported for similar analyses [8], to pre-
serve patient privacy, the identification codes from all
the databases were converted to anonymous codes, and
the conversion table was then destroyed.
Study population and design
From the regional prescription database we identified all
individuals aged ≥ 18 starting a new treatment with AP
drugs from 1 January 2012 to 31 December 2013. AP
drugs were defined as all drugs belonging to the N05A
Anatomical Therapeutic Chemical Classification (ATC)
group (with the exception of N05AN, lithium). New AP
users were individuals with no AP prescriptions in the
12 months before the first prescription issued in the
study period. From the group of new AP users, patients
with a recorded diagnosis from hospital discharge forms
of neoplasm (ICD9-CM 140–239), hip fracture (81.xx),
pulmonary embolism or deep vein thrombosis (415.xx,
453.xx, 451.1x) in the year before the first AP prescrip-
tion were excluded.
Each member of the cohort was followed from the first
AP prescription until the earliest of the following event:
outcome of interest (PE), death for any cause, emigration
and end of follow-up.
Selection of cases and controls
Cases were all cohort members who were hospitalized
for non-fatal or fatal PE during follow-up (ICD9-CM
codes 415.xx). For cases with more than one hospital ad-
mission for PE during follow-up, we selected the first
record of PE. Up to 20 controls for each case were ex-
tracted from the study cohort using incidence density
sampling and matched by age at cohort entry andgender. All controls were alive and at risk of the out-
come of interest at the date of the first PE in their
matched case (index date). Cases and controls with preg-
nancy (ICD9-CM codes 630–677), leg/hip fracture or a
diagnosis of neoplasm in the three months before the
index date were excluded. In agreement with Parker
and colleagues [10], controls with any prescriptions of
warfarin or other antithrombotic drug use (ATC code
B01AA03/B01AA07) before the index date were ex-
cluded. For cases, prescriptions for warfarin or other
antithrombotic drugs in the six weeks before the index
date did not trigger exclusion as they could plausibly be
treatment for the index event itself [10]; however we ex-
cluded cases with any use of warfarin or other antithrom-
botic drugs earlier than this six week period.
Assessment of AP exposure
We assessed exposure to AP drugs on the basis of pre-
scriptions on or before the index date. Each individual
was classified for exposure to AP as current user (one or
more prescriptions within three months before index
date); recent user (one or more prescriptions in the
period between 4 and 12 months before index date); past
user (one or more prescriptions 13 months or more be-
fore index date). Exposure during the past three months
was classified according to AP type (conventional only,
atypical only, both), formulation (oral, acute injection,
long-acting injection), number of AP scripts, number of
different AP prescribed, and overall amount of AP ex-
posure, calculated by dividing the total amount of pre-
scribed drug by the recommended daily dose, according
to each agent’s defined daily dose (DDD). The DDD is a
theoretical unit of measurement defined as the assumed
average maintenance daily dose for a drug, used for its
main indication in adults [11].
Data analysis
Using the whole study cohort, we estimated the rate ra-
tios with 95% confidence intervals (CIs) for the associ-
ation between PE and AP exposure, taking past use as
the reference category.
For the case–control analysis, cases and controls were
compared using chi-square test, for categorical data, and
t test for continuous data. We undertook multiple con-
ditional logistic regression to estimate the odds ratio
(OR), with 95% CIs, for the association between PE and
AP use. Subgroup analyses were performed for age
(≥65 years, < 65 years) and gender. ORs were adjusted
for the following confounding variables: psychiatric
hospitalization (ICD9-CM code 290–319); hospitalization
for coronary heart disease (410.xx-414.xx), heart failure
(428.xx), stroke (431.xx, 433.xx-436.xx), chronic liver
disease (570–573), chronic renal disease (584–586),
Parkinson’s disease (ICD9-CM code 332 or drug
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249–250 or drug prescription with ATC code A10); prescrip-
tion of lithium (ATC code N05AN01), statins (C10AA),
NSAIDs (M01A), antiplatelet treatment (A01AD05,
B01AC06, N02BA01, B01AB, B01AC04, B01AC05), and
antihypertensive agents (C02, C03,C07,C08,C09). All
covariates were considered in the 12 months before
index date. We did not adjust for varicose veins, in-
flammatory bowel disease, and use of hormone replace-
ment therapy, as suggested by Parker [10], as only very
few cases with these disorders were recorded.
Numbers needed to harm and extra cases per 10 000
treated were estimated, using the incidence of PE in the
past users and the adjusted ORs from current users.
Finally, in order to provide a summary of the whole
evidence base, we added the results of the present case–
control study to a recently published meta-analysis ofFigure 1 Flow chart of inclusion and exclusion criteria of cohort of new treobservational studies on the risk of PE outcomes associ-
ated with AP exposure (Additional file 1) [7]. A meta-
analysis influence test that eliminated each of the
included studies one at a time was carried out to test for
possibly excessive influence of individual studies.
Data management and analyses were carried out using
SAS statistical package (SAS Institute, Cary, NC), version 9.2
and Comprehensive Meta-Analysis version 2: the PHREG
procedure with STRATA statement was used to fit the con-
ditional logistic regression models. All tests were two-tailed,
and results were considered significant at p < 0.05.
Results
Study cohort
During the study period 144,129 individuals received
one or more AP prescriptions; of these, 84,253 were new
users and fulfilled the inclusion criteria (Figure 1). Theated with antipsychotic drugs in Lombardy Region from 2012 to 2013.
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up (a mean of 1 year per patient) and generated 269 PE
events, with an incident rate of 305 cases for 100 000
person-years at risk (Additional file 2).
Cases and controls
Of the 269 individuals with a recorded PE event, 232
were eligible as cases, and were matched with 4,353 con-
trols from the same study cohort (Figure 1). Cases and
controls were well matched by age and gender (Table 1).
Cases were more likely than controls to have admissions
for psychiatric disorders and for other medical condi-
tions, and were more often prescribed antiplatelet and
antihypertensive treatment.
Risk associated with AP drugs
Compared to past use, current AP use more than double
the risk of PE (OR 2.31, 95% CI 1.16 to 4.59), while re-
cent use did not increase with the risk of PE outcomes
(OR 0.96, 95% CI 0.44 to 2.07) (Table 2). Both conven-
tional and atypical AP exposure was associated with an
increase in risk, and the concomitant use of both AP
classes increased the risk of four times (OR 4.21, 95% CITable 1 Characteristics of cases (patients with first record of






Mean age ± SD 77.1 ± 13.5 76.9 ± 13.7 0.798
Age≥ 65 194 (83.6%) 3,610 (82.9%)
Age < 65 38 (16.4%) 743 (17.1%)
Women 157 (67.7%) 2,950 (67.8%) 0.975
Men 75 (32.3%) 1,403 (32.2%)
Hospitalization§
Mental disorders 72 (31.0%) 468 (10.8%) <.001
Coronary heart disease 22 (9.5%) 114 (2.6%) <.001
Heart failure 21 (9.1%) 118 (2.7%) <.001
Stroke 12 (5.2%) 108 (2.5%) 0.012
Chronic liver disease 5 (2.2%) 19 (0.4%) 0.000
Parkinson’s disease 32 (13.8%) 481 (11.0%) 0.197
Chronic renal disease 20 (8.6%) 90 (2.1%) <.001
Drug use§
Lithium 5 (2.2%) 84 (1.9%) 0.808
Statins 39 (16.8%) 744 (17.1%) 0.912
NSAIDs 67 (28.9%) 1,036 (23.8%) 0.078
Antiplatelet treatment 123 (53.0%) 1,981 (45.5%) 0.025
Anti-diabetic 34 (14.7%) 613 (14.1%) 0.807
Antihypertensive agents 155 (66.8%) 2,608 (59.9%) 0.036
*chi-square statistics.
§ in the 12 months preceding index date.
NSAIDs = non-steroidal anti-inflammatory drugs.1.53 to 11.59) (Table 2). The total number of AP pre-
scribed, and the overall amount of AP prescribed,
expressed as multiples of the DDD, were also significant
risk factors of PE (Table 2).
As the vast majority of cases and controls received oral
formulations, we were not able to calculate precise esti-
mates for acute and long-acting injections.
Subgroup analyses showed that the higher risk was in
women aged 65 or above (OR 4.96, 95% CI 1.55 to 15.9)
(Table 3). Table 4 shows the numbers needed to treat to
harm (NNH) for each category of AP exposure and the
number of excess cases per 10 000 patients treated over
a year. For example, the NNH for current AP exposure
was 624 (404 to 1,365); for patients aged 65 year and
older was 244 (178 to 388), for women was 326 (237 to
520), and for women older than 65 years was 160 (121
to 236). The corresponding numbers of excess cases of
PE per 10 000 treated patients were 16 (7 to 25), 41 (26
to 56), 31 (19 to 41), and 62 (42 to 83), respectively
(Table 4).
Meta-analysis of observational studies
According to a meta-analysis published in 2013, expos-
ure to APs did not significantly increase the risk of PE
(three studies, OR 4.90, 95% CI 0.77 to 30.98), but the
confidence interval was very wide and included the pos-
sibility of substantial harm. Adding the result of the
present case–control study yielded a random-effects OR
of 3.69 (95% CI of 1.23 to 11.07) with high-level of het-
erogeneity (I2 statistics = 90%) (Figure 2 and Additional
file 3).
Discussion
This nested case–control study, based on administrative
and clinical records of individuals resident in the region
of Lombardy in northern Italy, found a more than
double increased risk of PE for individuals prescribed
AP drugs in the past three months. The increase in risk
was more than three-fold for individuals aged 65 or
above, almost four times for women, and almost five
time for women aged 65 or above. The overall absolute
risk, however, was relatively low, with an excess of 16
extra cases of PE per 10 000 patients treated over one
year; however, in women aged 65 or above the risk rises
up to 62 extra cases of PE per 10 000.
Of 13 studies included in a recent systematic review
and meta-analysis, only three analysed PE outcomes.
The present study, therefore, significantly expands previ-
ous knowledge on this compelling issue. We showed
that adding these results to those of the three observa-
tional studies [7] substantially changed the overall esti-
mate, which now indicates that AP exposure increases of
more than three times the risk of PE, with a narrower
and statistically significant confidence interval.







P value Adjusted* odds
ratio (95% CI)
P value
Category of antipsychotic exposure:
Current 195 (84.1%) 2,956 (67.9%) 2.91 (1.48 - 5.73) 0.002 2.31 (1.16 - 4.59) 0.017
Recent 28 (12.1%) 1,002 (23.0%) 1.24 (0.58 - 2.64) 0.585 0.96 (0.44 - 2.07) 0.910
Past∫ 9 (3.9%) 395 (9.1%) 1 1
Class of antipsychotic received: (within past 3 months)
Conventional only 53 (22.8%) 507 (11.6%) 4.67 (2.27 - 9.61) <0.001 3.52 (1.69 - 7.35) 0.001
Atypical only 134 (57.8%) 2,386 (54.8%) 2.49 (1.26 - 4.93) 0.009 2.01 (1.01 - 4.03) 0.048
Both 8 (3.4%) 63 (1.4%) 5.66 (2.11 - 15.17) 0.001 4.21 (1.53 - 11.59) 0.005
No of antipsychotic scripts received: (within past 3 months)
1 96 (41.4%) 1,504 (34.6%) 2.82 (1.41 - 5.65) 0.003 2.19 (1.08 - 4.42) 0.029
≥2 99 (42.7%) 1,452 (33.4%) 3.01 (1.5 - 6) 0.002 2.44 (1.21 - 4.93) 0.013
No of different antipsychotic drugs received:
(within past 3 months)
1 178 (76.7%) 2,857 (65.6%) 2.74 (1.39 - 5.4) 0.004 2.19 (1.1 - 4.36) 0.025
≥2 17 (7.3%) 99 (2.3%) 7.68 (3.32 - 17.75) <0.001 5.87 (2.48 - 13.89) <0.001
DDDs: (within past 3 months)
<15 82 (35.3%) 1,440 (33.1%) 2.48 (1.23 - 5) 0.011 1.96 (0.96 - 3.99) 0.064
≥15 113 (48.7%) 1,516 (34.8%) 3.31 (1.66 - 6.6) 0.001 2.62 (1.3 - 5.25) 0.007
Formulation: (within past 3 months)
Oral 188 (81.0%) 2,822 (64.8%) 2.95 (1.5 - 5.81) 0.002 2.34 (1.17 - 4.64) 0.016
Acute injection 5 (2.2%) 97 (2.2%) 2.28 (0.75 - 6.95) 0.147 2.05 (0.66 - 6.37) 0.215
Long-acting injection 0 (0.0%) 22 (0.5%) - -
*adjusted for psychiatric hospitalization, coronary heart disease, heart failure, stroke, chronic liver disease, Parkinson’s disease, chronic renal disease, use of lithium,
statins, NSAID, antiplatelet treatment, antidiabetic and antihypertensive treatment.
∫reference category for all odds ratios.
CI = confidence interval.
DDDs = defined daily dose.
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was based on a large and representative population co-
hort, extracted from an administrative database covering
a population of almost ten million inhabitants, avoiding
bias from selection, non-response, or poor recall. This
administrative database has been shown to have good
levels of accuracy and completeness in recording pre-
scriptions and clinical diagnoses [8,9,12,13]. In thisTable 3 Risk of pulmonary embolism associated with
antipsychotic use: subgroup analysis for age and gender
Adjusted* odds ratios (95% confidence
interval) for current use vs past use for
each subgroup
age < 65 age ≥ 65 Total
Women 0.77 (0.08 - 7.17) 4.96 (1.55 - 15.9) 3.94 (1.43 - 10.88)
Men 0.5 (0.13 - 1.93) 1.7 (0.39 - 7.31) 1.03 (0.4 - 2.68)
Total 0.6 (0.19 - 1.89) 3.65 (1.48 - 9.04) 2.31 (1.16 - 4.59)
*adjusted for psychiatric hospitalization, coronary heart disease, heart failure,
stroke, chronic liver disease, Parkinson’s disease, chronic renal disease,
utilization of lithium, statins, NSAID, antiplatlet treatment, antidiabetic and
antihypertensive agents.system underreporting is unlikely, as data are used for
reimbursement reasons.
Second, unlike previous studies that used composite
outcome measures that include diagnostic codes related
to venous thromboembolism and PE, with the advantage
of increasing statistical power, we selected PE outcomes
only, based on clinical grounds, as we reasoned that this
is a major healthcare problem, causing over 300,000
deaths annually in Europe alone [2].
A third strength is that not only we adjusted for many
potential confounding factors, but also we a priori ex-
cluded individuals with characteristics that might be asso-
ciated with the outcome of interest, namely those with
neoplasm, hip fractures and PE or venous thromboembol-
ism in the year preceding the index date. We also ex-
cluded controls with any prescriptions for warfarin before
the index date, as this could be treatment for a previous
venous thromboembolism. According to Parker and col-
leagues, prescriptions for warfarin in the six weeks before
diagnosis of PE did not trigger exclusion for cases, as they
could plausibly be treatment for the index event itself
Table 4 Numbers needed to harm and extra cases per 10








overall population 624 (404 to 1,365) 16 (7 to 25)
age ≥ 65 244 (178 to 388) 41 (26 to 56)
Women 326 (237 to 520) 31 (19 to 42)
age ≥ 65 and women 160 (121 to 236) 62 (42 to 83)
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than this six week period, however, were excluded.
Finally, we had access to full prescription details for all AP
drugs, including drug name and formulation, dose instruc-
tions, and purchase date. This enabled us to look in detail at
characteristics of the drug exposure in relation to risk.
Unlike other studies, we were not able to adjust our
estimates for some confounding factors such as smoking
history, alcohol consumption, and body mass index,
which could play a role in the development of PE out-
comes [1-4]. However, in order to mitigate this limita-
tion, we employed a nested design by incorporating a
case–control approach within an established cohort of
individuals who were exposed to AP drugs. This design
overcomes some of the disadvantages associated with
case–control studies while incorporating some of the ad-
vantages of a cohort study. In particular, confounding by
indication is less likely, as all subjects were exposed to
the variable of interest [14].Figure 2 Random-effects meta-analysis on the risk of pulmonary embolismSimilarly to other studies, we failed to adjust for some
other potential confounding variables, including for
example physical activity and inactivity which are well-
known risk factor of PE [15]. Additionally, no adjust-
ment was possible for medicines not reimbursed by the
National health System, such as for example oral contra-
ceptives, as these are not stored into the administrative
databases. Another study limitation is that we had no
possibility to access psychiatric diagnoses, which might
also be associated with PE outcomes, as recently reported
by Parker and colleagues [10]. We were able to include, as
a confounding factor, psychiatric hospitalization, but we
acknowledge that this may only be considered a proxy
measure of psychiatric diagnoses.
As with all analyses of prescription databases, the lack
of data on whether patients eventually took the pre-
scribed agents should be highlighted, since a relevant
proportion of the medicines prescribed for people with
chronic conditions are not taken [16].
The biological mechanisms explaining the relationship
between AP drugs and PE are unknown [17]. It has been
suggested that all conditions associated with inactivity or
immobilization may be involved. Patients might be
immobilized due to the sedative properties of most AP
drugs, and AP drugs may also cause weight gain which
can increase inactivity and immobilization. Other bio-
logical mechanisms include raised levels of antiphospho-
lipid antibodies and hyperhomocysteinemia, which are
factors associated with PE outcomes, and might also be
associated with AP exposure [17].associated with exposure to antipsychotic drugs.
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Our findings add to the available body of evidence on
the risk of PE in individuals exposed to AP drugs. The
three studies available on this compelling issue are
highly heterogeneous, as two found an increased risk of
more than ten times, while one found a minimal in-
crease in risk, yielding a very imprecise and statistically
non significant overall estimate. Adding our study to the
forest plot increased the precision of the estimate, and
demonstrates that exposure to AP drugs significantly in-
creases the risk of developing PE.
Clinical interpretation of this increased risk is difficult.
The main finding of around 16 extra cases of PE per 10 000
patients prescribed AP drugs, or, in other words, the finding
that a doctor would need to prescribe AP drugs to around
600 individuals to see one extra case of PE, would suggest
that this risk may not be a major consideration when decid-
ing whether AP drugs should be used. However, in specific
populations, such as those aged 65 or above and women,
the risk is less irrelevant, also taking into consideration that
PE may be a life-threatening condition.
Additionally, very often a compelling decision is not
whether AP drugs should be used but, rather, which one
is less harmful. We found that both first- and second-
generation AP drugs carry an increased risk of PE, but
there might be differences among individual agents. We
recognize that this analysis is statistically less powerful,
so that for AP drugs that were not associated with an in-
creased risk we cannot exclude a type-II error, that is
failure to detect a difference, if a difference existed.
In conclusion, these data suggest that the expanding use
of AP drugs to treat conditions other than approved indi-
cations should require careful consideration of the poten-
tial harmful consequences of AP drugs, including a small
but significant increased risk of PE events. Patients need
information on the balance of risks and benefits of these
drugs before they start treatment. When treatment is
needed for approved indications, clinicians should be
aware that AP drugs should cautiously be used, especially
among patients at high risk of PE, for example by using
minimal effective doses and avoiding polypharmacy, as we
observed that dose and use of two or more AP drugs sub-
stantially increased the risk. Clinicians should additionally
be aware that, as with all other adverse events associated
with AP drugs [18], not all drugs are equally harmful.Additional files
Additional file 1: Meta-analysis of observational studies on the risk
of pulmonary embolism associated with antipsychotic exposure:
methods.
Additional file 2: Incidence of first hospital admission for pulmonary
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